The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Open accessAbstract
Purpose: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy. Patients and Methods: We identified 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007. Patients were compared by groups: 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondiabetic patients. pCR rates were compared between the three groups using χ 2 tests of independence and compared pair- wise using a binomial test of proportions. Factors predictive of pCR were assessed using a multivariate logistic regression model. Results: The rate of pCR was 24% in the metformin group, 8.0% in the nonmetformin group, and 16% in the nondiabetic group (P = .02). Pairwise comparisons between the metformin and nonmetformin groups (P = .007) and the nonmetformin and nondiabetic groups (P = .04) were significant. Comparison of the pCR rates between the metformin and nondiabetic groups trended toward but did not meet significance (P = .10). Metformin use was independently predictive of pCR (odds ratio, 2.95; P = .04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Conclusion: Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin. Additional studies to evaluate the potential of metformin as an antitumor agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin has also been found to cooperate with neo-adjuvant chemotherapy to result in complete tumor regression in some breast cancer patients (Jiralerspong et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Jiralerspong et al., 2009
In the citing paper
“Type 2 diabetic patients receiving neo-adjuvant chemotherapy for breast cancer as well as metformin were more likely to have pathologic complete response (pCR) than patients not receiving it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“However, despite the increase in pCR, metformin did not significantly improve the estimated 3-year relapse-free survival rate [156].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“There is further evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270), and there are now more than 100 ongoing trials”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“Metformin treatment was associated with higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy (95).”
From Diabetes and Cancer (2010) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Insulin-like growth factors and neoplasia
Pollak, M., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1387 · Cited by 1,477
Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Research works printed but not linked: 3
- Mieog JS, 2007, Cochrane Database Syst Rev, 2, CD005002
- 10.1200/JCO.2002.20.1.42 · DOI
- Fairey AS, 2003, Cancer Epidemiol Biomarkers Prev, 12, 721
Cited by
Sorted by citations
Items 701–800 of 879
Liu, L., Gao, Y., Liu, P., Hui, R., & Zhang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-14077-x · Cited by 2
Liu, M. D., Dong, Y., Guan, Q., Wang, J., Shi, Q., Lin, R., Zhang, M., Fu, D., Cheng, S., Xu, P. P., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70309 · Cited by 2
“Consistently, clinical trials have demonstrated the efficacy of metformin in enhancing the prognosis for various tumour types, including breast, lung, and bladder cancers, as well as DLBCL (Fan et al. 2018 ; Mazzone et al. 2012 ; Jiralerspong et al. 2009 ; Peng et al. 2016 ; Shi et al. 2012 ).”
Obesity and Insulin Resistance in Breast Cancer: Are Clinical Trials Needed?
Goodwin, P. J. (2012) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2012.10.026 · Cited by 2
Novel Therapies Metformin: The sweet link between tumor genetics and metabolism?
Nowak, K. L., Eldredge-Hindy, H., & Champ, C. (2014) · Cited by 2
Application of In Silico Drug Repurposing in Infectious Diseases
Kumar, P., & Ghosh, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00015-8 · Cited by 2
AHMED, S., ELSHENAWY, M. D. D. M. M. A. A., & ABDEEN, M. D. M. A. M. (2021) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2021.185030 · Cited by 2
Prieto, P. D. L. A. J., Álvarez-Bañuelos, M. T., Morales‐Romero, J., Cuevas-Córdoba, B., Sampieri, C. L., Zenteno‐Cuevas, R., & Guzmán-García, R. E. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108249 · Cited by 2
Park, J. S., Moon, S. J., Park, H. S., & Cho, S.-H. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102928 · Cited by 2
Abbes, A., Boudemia, R., & Rechreche, H. (2023) · Journal of Applied Biological Sciences · doi:10.71336/jabs.1090 · Cited by 2
“This effect was particularly clear in diabetic women treated with Met compared to those who were not [57].”
Repurposing Metformin for Lung Cancer Management
Chen, C., Wang, J.-L., Tsai, Y.-T., Jiang, J.-H., & Chen, H. (2017) · InTech eBooks · doi:10.5772/67160 · Cited by 2
“For breast cancer patients, some studies found that metformin was beneficial for neoadjuvant chemotherapy groups [5,6].”
BackgroundHaq, M. E. U., Akash, M. S. H., Rehman, K., & Khurshid, M. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2019-0318 · Cited by 2
“The evidences show that the risk of cancer is increased by glucose intolerance and insulin resistance [18].”
BackgroundDrug Repositioning for the Treatment of Glioma: Current State and Future Perspective
Tamai, S., Hirai, N., Jiapaer, S., Furuta, T., & Nakada, M. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92803 · Cited by 2
“The antitumor effects of metformin are widely known and reported in various cancers, such as breast cancer [10].”
BackgroundThe Biology of the Deadly Love Connection Between Obesity, Diabetes, and Breast Cancer
Bao, B., Oraha, A., Ahmad, A., Ali, S. S., Li, Y., Azmi, A. S., Banerjee, S., & Sarkar, F. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5647-6_7 · Cited by 2
“formin had a pathologic complete response rate of 24 % as compared to 8 % of the patients who did not receive metformin [148].”
BackgroundInfluence of metformin therapy on breast cancer incidence and prognosis
Popovic, Ð., POPOVIC, L. S., Stokić, E., Tomić-Naglić, D., Mitrović, M., & Kovačev-Zavišić, B. (2012) · Archive of oncology · doi:10.2298/aoo1204062p · Cited by 2
FASNating Targets of Metformin in Breast Cancer Stem-Like Cells
Wellberg, E. A., & Anderson, S. M. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0198-6 · Cited by 2
“Emerging data suggest that metformin treatment is associated with reduced breast cancer incidence and mortality for individuals with type II diabetes [7, 6, 17].”
BackgroundMetformin and Cancer Treatment
Mari, A. D., Bordonaro, S., Giuliano, S. R., Romano, F., Lanteri, E., & Tralongo, P. (2015) · World Journal of Oncology · doi:10.14740/wjon868w · Cited by 2
“Diabetic patients with breast cancer receiving metformin concomitant with neoadjuvant chemotherapy have a higher pCR rate than those non-receiving metformin [7].”
BackgroundUse of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article.
Raana, S., & Javeed, A. (2015) · PubMed · Cited by 2
Obesity, Type 2 Diabetes and Cancer
Ferguson, R. D., & LeRoith, D. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0598-6_3 · Cited by 2
Emerging Link between Diabetes and Cancer
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2015) · Journal of General and Family Medicine · doi:10.14442/jgfm.16.3_170 · Cited by 2
Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Barlak, N., Şanli, F., Çapik, Ö., Tuysuz, E., Karataş, E. A., Türkez, H., & Karataş, Ö. F. (2019) · Clinical Cancer Drugs · doi:10.2174/2212697x06666190906165309 · Cited by 2
Targeting TP53 to augment therapeutic response in head and neck cancer
Osman, A. A., Lindemann, A., Wang, L., Frank, S. J., & Myers, J. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00004-4 · Cited by 2
Repurposing of Metformin as a Multifaceted and Multitasking Preventative and Treatment for Cancer
Chang, R. Y. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96101 · Cited by 2
Metformin and Cancer: Is This the End?
Gallagher, E. J., KASE, N. G., Bickell, N. A., & LeRoith, D. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.005 · Cited by 2
Metformine et cancer : passé, présent, avenir
Loubière, C., Dirat, B., Tanti, J., & Bost, F. (2014) · Obésité · doi:10.1007/s11690-014-0418-9 · Cited by 3
Jiralerspong, S., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8491 · Cited by 2
Self-citationMetformin for chemo-radio-sensitization of NSCLC
Tsakiridis, T. K., Skinner, H. D., Pond, G. R., Swaminath, A., & Wright, J. R. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.06.018 · Cited by 2
“[6] Jiralerspong S, Palla SL, Giordano SH, et al.”
BackgroundMetformin Induces Ferroptosis byInhibiting UFMylation of SLC7A11 in Breast CancerPreprint
Yang, J., Zhou, Y., Xie, S., Ji, W., Li, Z., Chen, L., Mao, M., Chen, C., Huang, A., Chen, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-446847/v1 · Cited by 2
Said, A. S. A., Al-Mutteleb, H. A. M. A., Abdeen, M. A. M., Hassan, M. A. A. R., & Ahmed, S. A. A. (2020) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2020.120446 · Cited by 1
“(6) study (22 % in metformin group and 16% and 49% in non-metformin group).”
BackgroundMethodResultInfluentialHong, J. W. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.1.12 · Cited by 1
Heydarnia, E., Sepasi, A., Asefi, N., Khakshournia, S., & Mohammadnejad, J. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03049-z · Cited by 1
“Receiving chemotherapy and metformin simultaneously in the early stage of breast cancer in diabetic patients showed a significant response compared to patients taking different diabetic drugs (Jiralerspong et al. 2009).”
Energy Metabolism and Cancer Pain: A Pathway to Innovative Treatment Strategies
Paerhati, H., Zhang, M., & Gu, L. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266430740251020110940 · Cited by 1
Breast Cancer Stem Cell: Translating to the Clinic
Ono, M., Fujiwara, Y., & Ochiya, T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2828-8_22 · Cited by 1
Staying a Step Ahead of Cancer
Nowsheen, S., Alexandros, G., & Eddy, S. (2012) · InTech eBooks · doi:10.5772/35771 · Cited by 1
“Other small molecules, such as metformin and tamoxifen, demonstrate anti-tumor activity against breast cancer (Goodwin, Ligibel and Stambolic 2009, Jiralerspong et al. 2009, Osborne 1998).”
BackgroundYaturu, S. (2013) · InTech eBooks · doi:10.5772/56419
Chlebowski, R. T. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0084-6 · Cited by 1
Thompson, C. F., Wang, M. B., Sanaiha, Y., Lai, C. P. T., Grogan, T., Elashoff, D. A., & John, M. A. S. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.45109 · Cited by 1
Finstad, S. E., McTiernan, A., Wist, E., Furberg, A., Al-Haidari, G., Perera, N. D., Fagerland, M. W., Schlichting, E., Sauer, T., Lømo, J., et al. (2013) · Advanced Studies in Medical Sciences · doi:10.12988/asms.2013.13009 · Cited by 1
Metformina y acidosis láctica: ¿asociación infrecuente o causalidad?
Laureano, F. C. S., & Ortega, M. C. A. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)64015-x · Cited by 1
Obesity and Gastrointestinal Cancer-related Factor
Kim, D. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.59.1.8 · Cited by 1
“0%였다.(23) 이는 비록 후향적 연구이기는 하지만 메트포 르민의 항암효과를 나타내는 결과라고 생각한다.”
Furukawa, M., Lee, L., Keijirou, U. E. D. A., & Funakoshi, A. (2012) · Suizo · doi:10.2958/suizo.27.145 · Cited by 1
Use of Biguanides to Improve Response to Chemotherapy
Sandulache, V. C., Yang, L., & Skinner, H. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0856-1_1 · Cited by 1
The obesity and breast cancer connection: advancing the agenda.
Chlebowski, R. T. (2011) · PubMed · Cited by 1
Relação da síndrome metabólica com o câncer de mama
Buttros, D. D. A. B., Uemura, G., & Nahás, E. A. P. (2013) · Revista Brasileira de Mastologia · doi:10.5327/z201300040001rbm · Cited by 1
An update on the effectiveness of metformin alone and with chemotherapy drugs on tumor cells
Al-Zahrani, N. S., Ali, E. M. M., Kalantan, A. A., & Zamzami, M. A. (2020) · European Journal of Cell Science · doi:10.34154/2020-ejcs-0201-10-19/euraass · Cited by 1
Qin, S., Ingle, J. N., Kim, W., Gao, H., Weinshilboum, R. M., & Wang, L. (2021) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000435 · Cited by 1
Mousavi-Koodehi, B., Darzi, L., Sadeghizadeh, M., Najafi, F., & Forouzandeh-Moghdam, M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120308 · Cited by 1
Metabolic Syndrome, Obesity and Cancer Risk
Cirulli, G. O., Larcher, A., Montorsi, F., & Martini, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-84752-4_8 · Cited by 2
Kalinsky, K. M., & Hershman, D. L. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.35 · Cited by 1
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Esteva, F. J. (2011) · Yearbook of Oncology · doi:10.1016/j.yonc.2011.10.013 · Cited by 1
Need for Specialized Interest in Food and Nutrition in Palliative Care
Tsiompanou, E. (2019) · CRC Press eBooks · doi:10.1201/9781315160627-1 · Cited by 1
Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers
Guimarães, I. D. S., Tessarollo, N. G., dos Santos, D. Z., de Souza, M. L. M., Henriques, T. B., Silva, I. V., & Rangel, L. B. A. (2017) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000299 · Cited by 1
Noto, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-4376-5_9 · Cited by 1
Metformin and Its Implication in Cancer Therapy
Mazilu, L., Stănculeanu, D. L., Gheorghe, A. D., Suceveanu, A., Parepa, I. R., Voinea, F., Catrinoiu, D., & Suceveanu, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88803 · Cited by 1
Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response
Hassinger, T. E., Berger, A. C., Christopher, A. N., Knisely, A. T., Mehaffey, J. H., Brenin, D. R., Schroen, A. T., & Showalter, S. L. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.10.043 · Cited by 1
Pharmacological interventions part IV: Metabolic modifiers
Koltai, T., Reshkin, S. J., & Harguindey, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819059-3.00016-2 · Cited by 1
Circulating tumor cells and drug history in primary breast cancer patients
Jurišová, S., Karaba, M., Minárik, G., Benca, J., Sedláčková, T., Manasova, D., Kaľavská, K., Pinďák, D., Mardiak, J., & Mego, M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.79 · Cited by 1
“Contrary to our study, metformin, front-line therapy for the treatment of type 2 diabetes, especially in overweight and obese patients, may reduce breast cancer incidence and improve prognosis by several potential mechanisms according to some preclinical data([24,25]).”
ResultVieira-Monteiro, H. D. A., Goulart-Citrangulo, S. M. T., Sobral‐Leite, M., Giacomin, L. C., & Vianna‐Jorge, R. (2013) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2013v59n3.502 · Cited by 1
Metformine et aspirine : de « nouveaux » traitements du cancer ?
Arrondeau, J., & Bost, F. (2013) · ONCOLOGIE · doi:10.1007/s10269-013-2319-1 · Cited by 1
“comparés aux patients non diabétiques, traités par chimiothérapie néoadjuvante [46].”
Bordeleau, L. J., & Gerstein, H. C. (2014) · Diabetes Care · doi:10.2337/dc14-1220 · Cited by 1
Reply to A. Vazquez-Martin et al
Goodwin, P. J., Ligibel, J. A., & Stambolic, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6033 · Cited by 1
Jiralerspong, S., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4292 · Cited by 1
Self-citationMetformin Therapy and Breast Cancer Incidence in the Hail RegionPreprint
Osman, M. E., Muqbel, T., Alenzi, A., Alenzi, S., Kalifa, N., Khojali, W. M. A., & Elagib, H. M. (2022) · Preprints.org · doi:10.20944/preprints202212.0244.v1
Metformin Therapy and Breast Cancer Incidence in the Hail RegionPreprint
Osman, M. E., Muqbel, T., Alenzi, A., Alenzi, S., Kalifa, N., Khojali, W. M. A., Elagib, H. M., Hussein, W., & Abdallah, M. H. (2023) · Preprints.org · doi:10.20944/preprints202212.0244.v2 · Cited by 1
The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
Lubik, A. A. (2011) · Faculty of Science and Technology; Institute of Health and Biomedical Innovation
Thyroid Cancer Stem Cells – Strategies for Therapeutic Targeting
Lin, R.-Y., Sewell, W., Spradling, K., Reeb, A. N., & Li, W. (2013) · Springer eBooks · doi:10.1007/978-94-007-6262-6_16
Insulin Resistance: Clinical Implications for Cancer Treatment and Prevention
Niraula, S., & Goodwin, P. J. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_12
“Retrospective evidence for a potential clinically important effect of metformin in human cancer has been reported by Jiralerspong et al. [ 140 ], who found pathologic complete response (pCR) rates to neoadjuvant systemic therapy in breast 12 Insulin Resistance: Clinical Implications for Cancer Treatment and Prevention…”
BackgroundCheckley, L. A. (2012) · Digital Commons-TMC (Texas Medical Center)
Eucker, J. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12117
Emerging Therapies for Esophageal Cancer
Orita, H., Brock, M. V., & Sato, K. (2012) · InTech eBooks · doi:10.5772/30655
“Importantly, diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy were found to have a higher pCR(Pathologic Complete Response) rate than diabetics not receiving metformin [91].”
BackgroundStrategies for Targeting Cancer Stem Cells
Mufson, R. A. (2015) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201500001
Exploring a therapeutic role for IGF1R inhibitors in triple-negative breast cancer
Offor, O. (2010) · Europe PMC (PubMed Central)
Gordon-Dseagu, V. (2014) · UCL Discovery (University College London)
Insulina glargina y riesgo de cáncer
Rigla, M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)72707-x
Metformin: "Old warrior for a new battle"
Jain, A. (2010) · Indian Journal of Cancer · doi:10.4103/0019-509x.73553
Stankowski‐Drengler, T. J., Stankowski, R. V., Engel, J. M., & Onitilo, A. A. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0066-y
“Despite the controversy surrounding the relationship of metformin exposure to breast cancer incidence, most studies of breast cancer prognosis suggest improvement following exposure to metformin [39–41], even in the absence of DM [41].”
BackgroundConfounding Factors of the Diabetes - Metformin - Cancer Relationship
Aldea, M. D., Craeiun, L., Popescu, T., Nenu, I., & Crivii, C. B. (2014) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2014-0029
“cancer who received metformin have a higher complete pathologic response rate to CTh when compared to diabetic patients with breast cancer treated with other glucose lowering agents and even when compared to breast cancer patients without diabetes [1].”
BackgroundResultMartı́n-Castillo, B., Vázquez‐Martín, A., Oliveras‐Ferraros, C., & Menéndez, J. A. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)62003-0
“From a molecular perspective, the study by Jiralerspong et al.72 has provided also a possible link between insulin use and the insulin lowering-related anti-cancer effects of metformin.”
BackgroundInfluentialNeoadjuvant chemotherapy for breast cancer: a role for short-term fasting?
Niu, J., & Weiss, G. J. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.49
Cancer and diabetes: new links and new challenges
Morganstein, D. L., & Feher, M. D. (2013) · Practice Nursing · doi:10.12968/pnur.2013.24.8.392
The Potential Molecular Therapeutic Approach in Targeting Ovarian Clear Cell Carcinoma
Ngan, D. W. C. H. Y. (2012) · Gynecology & Obstetrics · doi:10.4172/2161-0932.1000e103
“Clinically, retrospective data have found that diabetic patients with breast cancer receiving Metformin have better response under neoadjuvant chemotherapy [47].”
BackgroundThe Molecular Biology of Inflammatory Breast Cancer
la Vega, H. A., Ruíz‐García, E., Juarez-Sánchez, P., de la Garza-Salazar, J. G., & Arrieta-Rodríguez, Ó. G. (2012) · Springer eBooks · doi:10.1007/978-0-85729-991-8_9
Hillson, R. (2015) · Practical Diabetes · doi:10.1002/pdi.1919
Perspectives in the treatment of breast cancer in postmenopausal women who are overweight and obese
Troshina, E. A., Rumyantsev, P. O., Altashina, M. V., & Plokhaya, A. A. (2013) · Obesity and metabolism · doi:10.14341/2071-8713-3859
Durlach, V. (2011) · Médecine thérapeutique · doi:10.1684/met.2011.0332
DIRECT EFFECTS OF METFORMIN ON PI3K AND RAS SIGNALING IN ENDOMETRIAL CANCER
Iglesias, & David, A. (2012)
chemoresistance of prostate cancer cells due to IGFBP2
Biernacka, K. M., Uzoh, C. C., Zeng, L., Persad, R. A., Bahl, A. K., Gillatt, D. A., Perks, C. M., & Holly, J. M. P. (2013)
Teixeira, S. F., Silva, I. V., & Rangel, L. B. A. (2013)
Anti-diabetic treatment and cancer occurrence among patients with type II diabetes mellitus
Qiu, H. (2011) · doi:10.7282/t3930s81
“Our results are consistent with the reports from a cohort study [28] in which concomitant metformin therapy decreased the risk of malignancy associated with insulin and with another cohort study [22] in which metformin reduced risk from insulin on breast cancer response.”
BackgroundResultMetformin reduces cisplatin-mediated apoptosis in gastric adenocarcinoma cells
Amoli, J. S., Ghaffari, H., Heidari, M., & Lesan, V. (2013) · KAUMS Journal · Cited by 1
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Esteva, F. J. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.03.009
Mohanraj, L. (2013) · Postdoc Journal · doi:10.14304/surya.jpr.v1n5.5
“treated with metformin have a reduced risk for developing different types of cancer (7).”
BackgroundMetformin and Cancer: past, present, future
Loubière, C., Dirat, B., & Bost, F. (2014)
Editorial Insulina glargina y riesgo de cáncer
Rigla, M. (2016)
Wu, G., Zhang, X., Luo, Z., Yan, J., Pan, S., Ying, X., & Zhang, G.-F. (2015)
Characterizing the Metabolomic Effects of Pancreatic Cancer
Bathe, O. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408103-1.00014-5
Impact of Comorbidity on Treatment Decision Making and Outcomes
Lee, J. J., & Extermann, M. (2016) · Springer eBooks · doi:10.1007/978-981-10-1844-2_5
Cai, H. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wcfz-nr55
Systemic Therapies to Reduce the Risk of Recurrence in Early Breast Cancer: New Strategies
Chaabouni, N. K. E., Nikolaou, C., & Harries, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-41858-2_7
Metadata
- Authors
- Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Breast Medical Oncology, Biochemistry and Molecular Biology, Quantitative Sciences, Surgical Oncology, Pharmacy, Molecular and Cellular Oncology, and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Gynecology and Obstetrics, University of Muenster, Muenster, Germany.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3297-3302
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2736070
- OpenAlex
- W2171998898
- Cited by
- 880
- References
- 42
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 34 · 2022: 31 · 2021: 51 · 2020: 43 · 2019: 60 · 2018: 34 · 2017: 42 · 2016: 54 · 2015: 53 · 2014: 73 · 2013: 97 · 2012: 76
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Breast Cancer Research Foundation
- Amgen
- American Society of Clinical Oncology
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k23ca121994-03)
- National Cancer Institute (1K23CA121994-01), K23-CA121994, 1K23CA121994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- metformin, breast cancer, diabetes mellitus, neoadjuvant chemotherapy, pathological complete response, predictors of treatment response
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Remission Induction, Multivariate Analysis, Logistic Models, Survival Analysis, Treatment Outcome, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
